AlphAIAlphAI — Financial news for AI agents
gurufocus.com$PRAX

PRAX Initiated Coverage by JP Morgan -- Rating Set to Overweight

JP Morgan initiated coverage on Praxis Precision Medicine (PRAX) with an Overweight rating and a $700 price target. The company's GF Value™ suggests it is 2045.6% overvalued, with a GF Score™ of 40/100 indicating concerns about profitability and growth. PRAX is a clinical-stage biopharmaceutical company focused on CNS disorders, with a market cap of $6.93 billion. Some gurus hold positions, with 2 adding stakes recently.

Original reporting
gurufocus.com
Published Oct 16, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PRAX
Bullish
high confidence
Mentioned
$PRAX
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$PRAXBullishMed
01

Why it matters

The new Overweight rating and $700 target represent a significant shift in analyst sentiment, potentially prompting short‑term buying pressure.

02

Market read

Analyst coverage change is a primary catalyst for PRAX, likely influencing its near‑term price action.

03

What to watch

No revenue yet; high valuation multiples could limit upside if clinical milestones are delayed.

Relevance 7/10Novelty 6/10Timing: today

Background

Praxis Precision Medicine is a clinical‑stage biopharma focused on CNS disorders, currently unprofitable with a market cap of ~ $6.9B.

Company-level read

Ticker impact

$PRAXBullishHigh confidence
Context

JP Morgan initiated coverage on Praxis Precision Medicine with an Overweight rating and a $700 price target on Oct 15, 2026.

Expected impact

likely upward pressure as investors price in the new rating and target

Evidence & confidence

The fresh Overweight rating and high price target provide a concrete catalyst for buying interest.

Market effects

Sector

Highlights renewed investor interest in clinical‑stage biotech companies.

Regional

May boost sentiment for US‑listed biotech stocks in the Nasdaq.

Global

Limited to investors tracking US biotech sector.

Counterpoint

What could challenge this read

The GF Score and extreme overvaluation suggest caution despite the rating upgrade.

Key entities

  • company
    Praxis Precision Medicine

    Clinical‑stage biotech developing CNS therapies.

  • analyst_firm
    JP Morgan

    Initiated coverage with Overweight rating.

Read at source← All news

Related articles

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

livetradingnews.com
$PRAXMed

PRAX Initiated Coverage by UBS -- Price Target Announced at $706

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

gurufocus.com
$PRAXMed

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines (PRAX) reported Q2 2026 results on an earnings call. Cash and marketable securities rose to $1.4B at June 30, 2026. Q2 net loss was $83.7M, with $78M operating cash burn. Ulixacaltamide PDUFA is Jan. 29, 2027, relutrigine PDUFA Dec. 27, 2026. The POWER1 vormatrigine trial missed its primary endpoint.

fool.com
$PRAXMed

Show Me The Money: After An 800%+ Gain, PRAX Enters A High-Stakes Stretch

Praxis Precision Medicines (PRAX) says it is entering a key period with four late-stage assets and FDA Breakthrough Therapy Designations. Two candidates are under FDA review: Relutrigine (priority review, decision Dec 27, 2026) and Ulixacaltamide (decision Jan 29, 2027). Relutrigine peak DEE revenues are projected over $5B, Ulixacaltamide over $10B. Vormatrigine Phase 2/3 POWER1 missed a primary endpoint; POWER2 enrollment was paused and plans to restart are underway.

rttnews.com
$PRAXHighAI 8/10

Why is Praxis Precision Medicines stock surging today?

Praxis Precision Medicines (PRAX) shares rose 9.3% pre-open after the company reported Q2 2026 results and said the FDA completed mid-cycle reviews for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (PDUFA Dec 27, 2026) with no major safety or efficacy concerns and no advisory committee. FDA inspections had no Form 483 observations. Praxis reported about $1.4B cash and investments as of June 30, 2026 and received a third Breakthrough Therapy Designation for elsunersen.

investing.com